Article
FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy.
Cancer chemotherapy and pharmacology - 1 Aug 2001
Naoe T, Kiyoe H, Yamamoto Y, Minami Y, Yamamoto K, Ueda R, Saito H
Abstract excerpt
Fusion gene products such as PML-RARalpha and BCR-ABL generated by leukemia-specific chromosomal translocations have been identified as target molecules for the treatment of leukemia. Here we describe one possibility for extending the frontier of mechanism-based medicine for acute myeloid leukemia (AML). FLT3, a receptor tyrosine kinase (RTK) preferentially expressed in hematopoietic progenitor cells, frequently...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
